Miniatura

Fitxers

729272.pdf (1.86 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-10-07

Llicència de publicació

cc-by-nc-nd (c) Cucchiari, David et al., 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/201402

Humoral and Cellular Immune Responses After a 3-dose Course of mRNA-1273 COVID-19 Vaccine in Kidney Transplant Recipients: A Prospective Cohort Study.

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1097/TXD.0000000000001389

Resum

In kidney transplant recipients, there is discordance between the development of cellular and humoral response after vaccination against SARS-CoV-2. We sought to determine the interplay between the 2 arms of adaptive immunity in a 3-dose course of mRNA-1273 100 μg vaccine. Methods: Humoral (IgG/IgM) and cellular (N- and S-ELISpot) responses were studied in 117 kidney and 12 kidney-pancreas transplant recipients at the following time points: before the first dose, 14 d after the second dose' and before and after the third dose, with a median of 203 and 232 d after the start of the vaccination cycle, respectively. Results: After the second dose, 26.7% of naive cases experienced seroconversion. Before the third dose and in the absence of COVID-19, this percentage increased to 61.9%. After the third dose, seroconversion occurred in 80.0% of patients. Naive patients who had at any time point a detectable positivity for S-ELISpot were 75.2% of the population, whereas patients who maintained S-ELISpot positivity throughout the study were 34.3%. S-ELISpot positivity at 42 d was associated with final seroconversion (odds ratio' 3.14; 95% confidence interval' 1.10-8.96; P = 0.032). Final IgG titer was significantly higher in patients with constant S-ELISpot positivity (P < 0.001). Conclusions: A substantial proportion of kidney transplant recipients developed late seroconversion after 2 doses. Cellular immunity was associated with the development of a stronger humoral response

Matèries

Trasplantament renal, SARS-CoV-2, Vacunes, RNA, Immunoglobulines, Resposta immunitària

Matèries (anglès)

Kidney transplantation, SARS-CoV-2, Vaccines, RNA, Immunoglobulins, Immune response

Citació

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

CUCCHIARI, David, EGRI, Natalia, RODRIGUEZ ESPINOSA, Diana, MONTAGUD MARRAHI, Enrique, CASALS URQUIZA, Joaquim, RISCO ZEVALLOS, Jimena del, BODRO, Marta, VENTURA AGUIAR, Pedro, COFÁN PUJOL, Federico, CACHO, Judit, MOLINA ANDÚJAR, Alícia, ROVIRA JUÁREZ, Jordi, BAÑÓN MANEUS, Elisenda, RAMÍREZ BAJO, María josé, PÉREZ OLMOS, Anna, GARCIA PASCUAL, Marta, PASCAL I CAPDEVILA, Mariona, VILELLA I MORATÓ, Anna, TRILLA GARCÍA, Antoni, PALOU, Eduard, REVUELTA, Ignacio, JUAN, Manel, CAMPISTOL PLANA, Josep m., OPPENHEIMER SALINAS, Federico, MORENO, Asunción, MIRÓ MEDA, José m. (josé maría), BAYÉS, Beatriu, DIEKMANN, Fritz. Humoral and Cellular Immune Responses After a 3-dose Course of mRNA-1273 COVID-19 Vaccine in Kidney Transplant Recipients: A Prospective Cohort Study.. _Transplantation Direct_. 2022. Vol. 8, núm. 11, pàgs. e1389. [consulta: 21 de gener de 2026]. ISSN: 2373-8731. [Disponible a: https://hdl.handle.net/2445/201402]

Exportar metadades

JSON - METS

Compartir registre